NASDAQ:RGLS
Delisted

Regulus Therapeutics Stock Signals

etoro logo Buy RGLS
*Your capital is at risk
$8.16
+0 (+0%)
At Close: Sep 24, 2025

Latest Data & Signals Issued

Below are some of the latest signals issued for Regulus Therapeutics Inc.

General

Signal Type Signal Value Data
Score 0.000 66 days ( -0.246 %
Last Price $8.16 0 %
Performance History
7 Days
$8.16 $8.16
0%
30 Days
$8.16 $8.16
0%
12 Mos
$1.55 $8.16
426.45%

8/18

Active Buy Signals

Specific Signals

Short Term
Net score: 20.95
Signal Type Signal Value Importance Data
High / Low N/A Very Low $8.16 - $8.16
Trend - 3 mos 0 % High Width: 0 %
Pred. range - 3 mos N/A - N/A Low -100.00 % - -100.00 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Sep 23, 2025 - 2 days
RSI Short Pivot Signal Buy Very Low Jul 10, 2025 - 54 days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Sell Medium Jul 25, 2025 - 43 days
Short/Long MA 3 mos Sell Medium Jul 25, 2025 - 43 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 71.26
Signal Type Signal Value Importance Data
Trend - 12 mos 466.09 % Very High Width: 90.98 %
Pred. range - 12 mos $34.67 - $66.21 High 324.86 % - 711.38 %
Short MA 12 mos Sell Very High Jul 07, 2025 - 57 days
Long MA 12 mos Buy Very High Mar 26, 2025 - 126 days
Short/Long MA 12 mos Buy Very High Mar 31, 2025 - 123 days
Pivot Long Buy Low Jun 20, 2025 - 67 days
RSI Long Pivot Signal Buy Low Jul 21, 2025 - 47 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT REGULUS THERAPEUTICS INC.
Regulus Therapeutics
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.39% Jun 10
E
ETD
$20.67
4.79% Jun 05
EAT
$140.46
16.94% Jun 05
TPR
$140.47
7.16% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE